CING · Cingulate Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company can give no assurance that its plans will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above, which results in substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed May 14, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-07-30 |
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary |
| 2026-07-02 |
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery |
| 2026-06-25 |
Innovation is the Best Medicine: How CEO Shane Schaffer and Cingulate Developed “Precision Timed Release,” a New Drug Delivery Platform for ADHD
Source: Financial Tech Times |
| 2026-06-16 |
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Exclusivity Extended into December 2042 KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation |
| 2026-06-02 |
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE |
| 2026-05-14 |
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cash Position Grows to $25.9 Million KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported |
| 2026-05-04 | 2026 AMCP Poster |
| 2026-05-04 | 2025 AACAP Presentation |
| 2026-03-18 |
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision |
| 2026-02-17 |
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by |
| 2025-11-13 |
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-23 | What is CTx-1301? | Event |
| 2026-06-23 | Standing Out in a Competitive Environment | Event |
| 2026-06-23 | Cingulate’s Pre-Commercialization Efforts | Event |
| 2026-06-23 | Cingulate’s Mission In ADHD | Event |
| 2026-06-23 | Cingulate’s Complete Response Letter | Event |
| 2026-06-23 | Cingulate Resubmission | Event |
| 2026-02-05 | Cingulate’s Shane Schaffer: We Brought in the Experts | Event |
| 2026-02-05 | Cingulate’s Rick Arce Discusses Payor Strategy | Event |
| 2026-02-05 | Chief Commercial Officer Bryan Downey Discusses Cingulate’s Strategic Launch | Event |
| 2025-07-24 | Cingulate CEO Shane Schaffer Previews ADHD Documentary and more on the Big Biz Show | Event |
| 2025-06-16 | Major Operational Updates from Cingulate’s CEO and CMO | Event |
| 2025-05-29 | Cingulate's Indegene Commercialization Agreement | Event |